WO2005037322A1 - 癌遺伝子治療薬 - Google Patents
癌遺伝子治療薬 Download PDFInfo
- Publication number
- WO2005037322A1 WO2005037322A1 PCT/JP2004/015221 JP2004015221W WO2005037322A1 WO 2005037322 A1 WO2005037322 A1 WO 2005037322A1 JP 2004015221 W JP2004015221 W JP 2004015221W WO 2005037322 A1 WO2005037322 A1 WO 2005037322A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- virus
- adenovirus
- carrier
- Prior art date
Links
- 108700020796 Oncogene Proteins 0.000 title claims abstract description 7
- 229940126585 therapeutic drug Drugs 0.000 title abstract description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 565
- 241000700605 Viruses Species 0.000 claims abstract description 131
- 244000309459 oncolytic virus Species 0.000 claims abstract description 62
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 48
- 241000701161 unidentified adenovirus Species 0.000 claims description 186
- 206010028980 Neoplasm Diseases 0.000 claims description 151
- 108700019961 Neoplasm Genes Proteins 0.000 claims description 68
- 102000048850 Neoplasm Genes Human genes 0.000 claims description 68
- 230000003053 immunization Effects 0.000 claims description 67
- 239000003814 drug Substances 0.000 claims description 66
- 238000001415 gene therapy Methods 0.000 claims description 64
- 201000011510 cancer Diseases 0.000 claims description 52
- 229940079593 drug Drugs 0.000 claims description 48
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 34
- 230000036039 immunity Effects 0.000 claims description 27
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 20
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 19
- 108010045569 atelocollagen Proteins 0.000 claims description 18
- 229940124597 therapeutic agent Drugs 0.000 claims description 17
- 239000013604 expression vector Substances 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 229910052742 iron Inorganic materials 0.000 claims description 11
- 230000004044 response Effects 0.000 claims description 10
- 102000016776 Midkine Human genes 0.000 claims description 9
- 108010092801 Midkine Proteins 0.000 claims description 9
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 101000701902 Homo sapiens Serpin B4 Proteins 0.000 claims description 6
- 241001430294 unidentified retrovirus Species 0.000 claims description 6
- 101000642478 Homo sapiens Serpin B3 Proteins 0.000 claims description 5
- 101150071146 COX2 gene Proteins 0.000 claims description 4
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 claims description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 101150000187 PTGS2 gene Proteins 0.000 claims description 4
- 241000713666 Lentivirus Species 0.000 claims description 3
- 102100030326 Serpin B4 Human genes 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241000702244 Orthoreovirus Species 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 50
- 238000001727 in vivo Methods 0.000 abstract description 8
- 238000000338 in vitro Methods 0.000 abstract description 5
- 239000012050 conventional carrier Substances 0.000 abstract description 3
- 230000003389 potentiating effect Effects 0.000 abstract description 2
- 238000002649 immunization Methods 0.000 description 56
- 230000000694 effects Effects 0.000 description 53
- 241000699670 Mus sp. Species 0.000 description 50
- 206010033128 Ovarian cancer Diseases 0.000 description 46
- 206010061535 Ovarian neoplasm Diseases 0.000 description 46
- 238000002474 experimental method Methods 0.000 description 45
- 241000699666 Mus <mouse, genus> Species 0.000 description 41
- 238000011282 treatment Methods 0.000 description 38
- 230000009422 growth inhibiting effect Effects 0.000 description 36
- 238000000034 method Methods 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 26
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 24
- 229960002749 aminolevulinic acid Drugs 0.000 description 24
- 208000015181 infectious disease Diseases 0.000 description 21
- 239000002245 particle Substances 0.000 description 20
- 230000003263 anti-adenoviral effect Effects 0.000 description 19
- 230000002401 inhibitory effect Effects 0.000 description 19
- 230000005855 radiation Effects 0.000 description 19
- 230000000174 oncolytic effect Effects 0.000 description 17
- 230000005917 in vivo anti-tumor Effects 0.000 description 14
- 238000011580 nude mouse model Methods 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 230000002601 intratumoral effect Effects 0.000 description 11
- 238000007920 subcutaneous administration Methods 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 241000699660 Mus musculus Species 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000003211 malignant effect Effects 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 230000005740 tumor formation Effects 0.000 description 8
- 238000007912 intraperitoneal administration Methods 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 208000003174 Brain Neoplasms Diseases 0.000 description 6
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 101710199711 Early E1A protein Proteins 0.000 description 4
- 102100036383 Serpin B3 Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000012830 cancer therapeutic Substances 0.000 description 4
- 230000007910 cell fusion Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 230000009036 growth inhibition Effects 0.000 description 4
- 230000000415 inactivating effect Effects 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 101150029662 E1 gene Proteins 0.000 description 3
- 108010089792 Hemeproteins Proteins 0.000 description 3
- 102000008015 Hemeproteins Human genes 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 241000702263 Reovirus sp. Species 0.000 description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 description 3
- 206010057644 Testis cancer Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000009702 cancer cell proliferation Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 230000008611 intercellular interaction Effects 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 201000003120 testicular cancer Diseases 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 241000024188 Andala Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 101150005585 E3 gene Proteins 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- -1 Porphyrin compounds Chemical class 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 201000008068 ovarian malignant mesothelioma Diseases 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 229950003776 protoporphyrin Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000002407 ATP formation Effects 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241001055367 Dario Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000021994 Diffuse astrocytoma Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 102100022898 Galactoside-binding soluble lectin 13 Human genes 0.000 description 1
- 101001011003 Gallus gallus Gallinacin-13 Proteins 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101000620927 Homo sapiens Galactoside-binding soluble lectin 13 Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 241000283080 Proboscidea <mammal> Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 210000002588 alveolar type II cell Anatomy 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FWZTTZUKDVJDCM-CEJAUHOTSA-M disodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);hydroxide;trihydrate Chemical compound O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FWZTTZUKDVJDCM-CEJAUHOTSA-M 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 201000001169 fibrillary astrocytoma Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940082629 iron antianemic preparations Drugs 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229940109328 photofrin Drugs 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 108010088201 squamous cell carcinoma-related antigen Proteins 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/575,894 US20070141028A1 (en) | 2003-10-15 | 2004-10-15 | Cancer gene therapeutic drug |
CA002542337A CA2542337A1 (en) | 2003-10-15 | 2004-10-15 | Cancer gene therapeutic drug |
JP2005514784A JP4423508B2 (ja) | 2003-10-15 | 2004-10-15 | 癌遺伝子治療薬 |
EP04792438A EP1676590A4 (en) | 2003-10-15 | 2004-10-15 | ANTICANCER TREATMENT MEDICINE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003354983 | 2003-10-15 | ||
JP2003-354983 | 2003-10-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005037322A1 true WO2005037322A1 (ja) | 2005-04-28 |
Family
ID=34463159
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/015221 WO2005037322A1 (ja) | 2003-10-15 | 2004-10-15 | 癌遺伝子治療薬 |
PCT/JP2004/015220 WO2005037321A1 (ja) | 2003-10-15 | 2004-10-15 | 癌遺伝子治療薬 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/015220 WO2005037321A1 (ja) | 2003-10-15 | 2004-10-15 | 癌遺伝子治療薬 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20070134202A1 (ja) |
EP (2) | EP1676589A4 (ja) |
JP (2) | JP4423508B2 (ja) |
KR (2) | KR100842658B1 (ja) |
CN (2) | CN100438920C (ja) |
CA (2) | CA2542335A1 (ja) |
WO (2) | WO2005037322A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100086522A1 (en) * | 2006-07-18 | 2010-04-08 | Ottawa Health Research Institute | Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses |
JP5187676B2 (ja) * | 2007-06-27 | 2013-04-24 | 国立大学法人名古屋大学 | 腹腔内腫瘍病変の治療又は予防用の医薬組成物 |
US8450106B2 (en) * | 2007-10-17 | 2013-05-28 | The Ohio State University Research Foundation | Oncolytic virus |
AU2013211871B2 (en) | 2012-01-25 | 2017-12-14 | Board Of Regents, The University Of Texas System | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
CN110042086A (zh) | 2012-02-02 | 2019-07-23 | 得克萨斯州大学系统董事会 | 表达异源肿瘤相关抗原的腺病毒 |
JP6358831B2 (ja) * | 2014-03-31 | 2018-07-18 | 雄行 濱田 | 新規細胞、それを用いた抗腫瘍効果の誘導剤、癌の遺伝子治療用医薬および抗腫瘍効果の誘導方法 |
CN106591361A (zh) * | 2015-10-20 | 2017-04-26 | 钱文斌 | 一种重组痘溶瘤病毒及其构建方法和应用 |
WO2019132594A1 (ko) * | 2017-12-29 | 2019-07-04 | 한양대학교 산학협력단 | 유전자 전달용 세포 시트 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999045783A1 (en) * | 1998-03-12 | 1999-09-16 | The Trustees Of The University Of Pennsylvania | Producer cells for replication selective viruses in the treatment of malignancy |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5837261A (en) * | 1990-09-25 | 1998-11-17 | Cantab Pharmaceuticals Research Limited | Viral vaccines |
US6403370B1 (en) * | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
US20020177551A1 (en) * | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
DE602004018927D1 (de) * | 2003-06-18 | 2009-02-26 | Genelux Corp | Modifizierte rekombinante vacciniaviren, verwendungen davon |
US7026164B2 (en) * | 2003-07-03 | 2006-04-11 | Cell Genesys, Inc. | Adenovirus packaging cell lines |
-
2003
- 2003-10-15 US US10/576,047 patent/US20070134202A1/en not_active Abandoned
-
2004
- 2004-10-15 KR KR1020067007092A patent/KR100842658B1/ko not_active IP Right Cessation
- 2004-10-15 KR KR1020067007091A patent/KR100798996B1/ko not_active IP Right Cessation
- 2004-10-15 EP EP04792437A patent/EP1676589A4/en not_active Ceased
- 2004-10-15 WO PCT/JP2004/015221 patent/WO2005037322A1/ja active Search and Examination
- 2004-10-15 EP EP04792438A patent/EP1676590A4/en not_active Ceased
- 2004-10-15 JP JP2005514784A patent/JP4423508B2/ja not_active Expired - Fee Related
- 2004-10-15 JP JP2005514783A patent/JP4423507B2/ja not_active Expired - Fee Related
- 2004-10-15 CA CA002542335A patent/CA2542335A1/en not_active Abandoned
- 2004-10-15 CN CNB200480030316XA patent/CN100438920C/zh not_active Expired - Fee Related
- 2004-10-15 WO PCT/JP2004/015220 patent/WO2005037321A1/ja active Application Filing
- 2004-10-15 CA CA002542337A patent/CA2542337A1/en not_active Abandoned
- 2004-10-15 US US10/575,894 patent/US20070141028A1/en not_active Abandoned
- 2004-10-15 CN CNB2004800303155A patent/CN100488567C/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999045783A1 (en) * | 1998-03-12 | 1999-09-16 | The Trustees Of The University Of Pennsylvania | Producer cells for replication selective viruses in the treatment of malignancy |
Non-Patent Citations (4)
Title |
---|
COUKOS G. ET AL.: "Use of carrier cells to deliver a replication-selective Herpes Simplex irus-1 mutant for the Intraperitoneal therapy of epithelial ovarian cancer", CLINICAL CANCER RESEARCH, vol. 5, 1999, pages 1523 - 1537, XP000979399 * |
HIRASAWA K. ET AL.: "Oncolytic reovirus against ovarian and colon cancer", CANCER RESEARCH, vol. 62, 2002, pages 1696 - 1701, XP001080172 * |
LAMBRIGHT E S, ET AL: "Onclolytic Therapy using a mutant Type-1 Herpes simplex virus and the role of the immune system", ANN. THORAC. SURG., vol. 68, 1999, pages 1756 - 1762, XP002985953 * |
TOTH K. ET AL.: "Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP(E3-11.6K) protein", CANCER GENE THERAPY, vol. 10, 2003, pages 193 - 200, XP002985954 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005037321A1 (ja) | 2006-12-28 |
KR20060096023A (ko) | 2006-09-05 |
CN100438920C (zh) | 2008-12-03 |
CA2542337A1 (en) | 2005-04-28 |
WO2005037321A1 (ja) | 2005-04-28 |
CA2542335A1 (en) | 2005-04-28 |
JPWO2005037322A1 (ja) | 2006-12-28 |
CN1867362A (zh) | 2006-11-22 |
EP1676590A1 (en) | 2006-07-05 |
KR100798996B1 (ko) | 2008-01-28 |
EP1676589A4 (en) | 2007-08-15 |
KR20060096024A (ko) | 2006-09-05 |
JP4423508B2 (ja) | 2010-03-03 |
CN100488567C (zh) | 2009-05-20 |
US20070141028A1 (en) | 2007-06-21 |
EP1676590A4 (en) | 2007-08-15 |
JP4423507B2 (ja) | 2010-03-03 |
EP1676589A1 (en) | 2006-07-05 |
US20070134202A1 (en) | 2007-06-14 |
KR100842658B1 (ko) | 2008-06-30 |
CN1867361A (zh) | 2006-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230203453A1 (en) | Modified oncolytic virus | |
CN109576231B (zh) | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 | |
US20090053186A1 (en) | Therapy for primary and metastatic cancers | |
US20080292592A1 (en) | Oncolytic Adenovirus Armed with Therapeutic Genes | |
AU2002222104B2 (en) | Photochemical internalization for virus-mediated molecule delivery into the cyosol | |
WO2014022138A2 (en) | Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator | |
Sinkovics et al. | Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers | |
JP2021045152A (ja) | 癌を治療するための治療用組成物及び使用方法 | |
JP7420751B2 (ja) | I型インターフェロン及びcd40-配位子を用いる腫瘍溶解性ウイルス又は抗原提示細胞媒介性癌治療 | |
JP4423507B2 (ja) | 癌遺伝子治療薬 | |
Spunde et al. | Recombinant viral vectors for therapeutic programming of tumour microenvironment: Advantages and limitations | |
CN111630159A (zh) | 重组腺病毒及包含此病毒的干细胞 | |
JP2006502726A (ja) | 改善された免疫療法 | |
JP6358831B2 (ja) | 新規細胞、それを用いた抗腫瘍効果の誘導剤、癌の遺伝子治療用医薬および抗腫瘍効果の誘導方法 | |
AU2004217830B2 (en) | A recombinant constructed by a virus vector and a human tumor suppressor gene and its use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480030316.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2542337 Country of ref document: CA Ref document number: 2005514784 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067007092 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007141028 Country of ref document: US Ref document number: 10575894 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004792438 Country of ref document: EP |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 2004792438 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067007092 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10575894 Country of ref document: US |